Recce Pharmaceuticals Achieves Positive Phase I Clinical Trial Data of RECCE® 327 as an Intravenous…
Highlights: Independent examiners confirm Phase I study of RECCE® 327 (R327) in 80 human subjects across eight cohorts achieved all primary study endpoints, met international regulatory standards, and demonstrated R327 to be safe and…